



SKIN CANCER (OTHER THAN MELANOMA)

DERMATOSCOPIC CLEARANCE OF ACTINIC KERATOSIS TREATED WITH INGENOL MEBUTATE. CASE REPORT.

F Daniele⁽¹⁾

Swiss Medical Center, Dermatology, Buenos Aires, Argentina⁽¹⁾

Introduction: Ingenol mebutate gel is a topical field treatment for actinic keratosis (AK) approved for a 2 or 3 days application. ANMAT approval in march 2018 for treatment in Argentina.

Objective: quantify the percentage of clearance of the actinic keratosis with ingenol mebutate single course treatment, in office consults, with a dermatoscopic hand tool.

Methods: a retrospective chart and dermatoscopic review for 5 patients treated with ingenol mebutate gel in 4 months.

Results: a total of 5 patients with extensive sun damage exposed areas and multiple AK were treated from May 2018 to July 2018. All of them had previous history of CBC and multiple past treatments for AK with a variety of therapies such as cryosurgery, ablative therapies, diclofenac 3% and 5-flourouracil. None of them ever cleared the remained lesions due to lack of adherence to topical treatments. After the 2 or 3 days single regimen with ingenol mebutate, 57% of the AK were cleared by dermatoscopic control at day 60.

Limitations: this is retrospective chart review of 5 patients with a single practice. Large series are needed.

Conclusion: 57 % of the lesions in this serie showed no dermatoscopic signs of AK remained after single course treatment with ingenol mebutate at day 60.

